Welcome to Plexision

PlexCMV

PlexCMV

Personalizing assessment of cell mediated immunity to Cytomegalovirus
Read More
Pleximmune

Pleximmune

Predicts the risk of acute cellular rejection after liver or intestine transplantation in children
Read More
Pleximark

Pleximark

Predicts the likelihood of acute cellular rejection after kidney transplantation.
Read More
Products & Services

Personalized Diagnostic Testing

Transplant Rejection
Icon

PleximmuneTM

PleximmuneTM : an FDA-approved blood test to predict the risk of acute cellular rejection after liver or intestine transplantation in children.

Read more

Icon

PleximarkTM

PleximarkTM : a blood test to assess the likelihood of acute cellular rejection after renal transplantation.

Read more

Icon

PlexABMRTM

PlexABMRTM : a blood test to assess the risk of antibody-mediated rejection of a transplanted organ.

Read more

Icon

PlexAPRTM

PlexAPRTM : a blood test to rapidly assess the risk of rejection after transplantation of abdominal organs.

Read more

Viral Infections
Icon

PlexCMVTM

PlexCMVTM : a blood test to measure the level of cellular immunity to Cytomegalovirus (CMV).

Read more

Icon

PlexEBVTM

PlexEBVTM : a blood test to measure the level of cellular immunity to Epstein-Barr virus (EBV).

Read more

Icon

PlexBKVTM

PlexBKVTM : a blood test to measure the level of cellular immunity to the BK variation of the polyomavirus.

Read more

COVID-19
Icon

PlexCOVID-19

PlexCOVID-19 : a lab-developed blood test to measure the level of cellular immunity to SARS-CoV-2. 

Read more

Icon

COVID-19 Antibody Testing

COVID-19 : a lab-developed blood test that detects the presence of antibodies to the SARS-CoV-2 virus.

Read more

Immune deficiency
Icon

Lymphocyte Subsets

A blood test to measure counts and relative frequencies of T-, B-and Natural-killer lymphocytes.

Read more

Icon

Antigen Stimulation

A blood test to measure T-cell immunity to common viruses, e.g. Cytomegalovirus and the Epstein-Barr virus.

Read more

Icon

Mitogen Stimulation

A blood test to measure a patient's general cellular immune response to common mitogens.

Read more

ImmunoOncology
Icon

Immuno-Oncology

A blood test to characterize tumor antigenicity, anti-tumor responses, and their modulation with specific immune checkpoint inhibitors.

Read more

Services
Icon

Biomarkers

Plexision performs custom R and D projects aimed at integrating biomarker targets in all phases of drug development.

Read more

Plexision Blog

Check out our latest news, media, and event related information

New blood test to predict antibody-mediated rejection to be presented at World Transplant Congress

SAN FRANCISCO — August, 2025. Antibody-mediated rejection causes severe graft injury and graft loss. New biomarkers are needed to manage this type of rejection. In a clinical trial conducted at three kidney transplant centers, the
PlexABMRTM test developed by Plexision predicted antibody-mediated rejection with positive and negative predictive values of 81% and 75%, respectively. Study results will be presented in San Francisco in early August, 2025 at the World Transplant Congress.

News
Read more
Rapid six-hour test panel to predict CMV infection and transplant rejection

Plexision, a biotechnology company, is offering the first blood test panel capable of reporting the risk of cytomegalovirus infection and transplant rejection within six hours after samples arrive at its reference laboratory.

News
Read more

logo

Developing cellular biomarkers for personalized diagnosis and drug development in infectious diseases, solid organ transplantation, as well as immunological disorders.

CONTACT US

  • Contact us
    4424 Penn Ave., #202,
    Pittsburgh, PA 15224 USA
  • Mail Us
    info@plexision.com
  • Phone
    +1 (855) 753-9474
© Copyright Plexision 2020. All Rights Reserved.

About

Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation and immunological disorders. We also pioneer in R&D projects centered on integrating biomarker targets in all phases of drug development, from preclinical to post-marketing. Plexision’s technology can be adapted to

  • - Assess disease risk for several immunological disorders.
  • - Predict the success of a drug for a specific patient.
  • - Develop dosing recommendations for new immunological drugs.

Our state-of-the-art laboratory is CLIA-certified and located in Pittsburgh, PA.

Contact